• Several modular elements assist the classification, evaluation, and analysis of the data on a shared platform
• A web‐based browser provides access for search inquiries on harmonized cohort data.
• The tools produced can operate locally at the data custodian site, maintaining local governance and provenance, ensuring data protection by design. These tools offer study-specific data extraction and anonymization.
The EMIF project intended to approach scientific issues in the field of obesity and AD, the so‐called use cases. At the same time leading the development of the EMIF tools and processes and examining the capability of data sources. Every use case had a dedicated research team. This team was responsible for the accurate execution of the use case within the agreed schedule. This team consisted of epidemiologists, medical experts, and data analysts, and data custodians. The team members were equally involved in both industry and academia. The collaboration between industry and academic partners also leads to increasing trust in the stakeholders.
The Effects Of This Data Management Project
Early biomarker development
Treatments for AD developed through the last twenty years have mostly failed to ameliorate the disease development. This has created a need for a different strategy, and focus on treating patients at earlier stages of the disease. Consequently, a lot of work is currently being conveyed on developing biomarkers for the earlier identification of AD. Mainly low invasive biomarkers like those in blood. The EMIF project endeavored to identify possible biomarker targets by ensuring the best use of the excess of immediately accessible AD cohort databases for research.
By reusing the AD patient data which was already available, the studies trying to identify a sound biomarker, have served to obtain more profound insights into disorder pathophysiology. EMIF has developed the AD biomarker field dramatically. Also, the tools that were developed are crucial to providing data access at the scale needed for collaborative studies on individuals with a preclinical AD phenotype.